Unlabelled: As an important epigenetic mechanism, histone acetylation modulates the transcription of many genes and plays important roles in hepatocellular carcinoma (HCC). Aberrations in histone acetylation have been observed in HCC, but the factors that contribute to the aberrations have not been fully elucidated. MicroRNAs (miRNAs), which are noncoding RNAs that regulate gene expression, are involved in important epigenetic mechanisms. In this study, we determined that miR-200a and the level of histone H3 acetylation at its promoter were reduced in human HCC tissues in comparison with adjacent noncancerous hepatic tissues. Furthermore, our results suggested that the histone deacetylase 4 (HDAC4) inhibited the expression of miR-200a and its promoter activity and reduced the histone H3 acetylation level at the mir-200a promoter through a Sp1-dependent pathway. Interestingly, we observed that the miR-200a directly targeted the 3'-untranslated region of the HDAC4 messenger RNA and repressed expression of HDAC4. Therefore, miR-200a ultimately induced its own transcription and increased the histone H3 acetylation level at its own promoter. Through targeting HDAC4, miR-200a also induced the up-regulation of total acetyl-histone H3 levels and increased the histone H3 acetylation level at the p21(WAF/Cip1) promoter. Finally, we determined that miR-200a inhibited the proliferation and migration of HCC cells in vivo and in vitro.
Conclusion: Our findings suggest that the HDAC4/Sp1/miR-200a regulatory network induces the down-regulation of miR-200a and the up-regulation of HDAC4 in HCC. As a result, down-regulation of miR-200a enhances the proliferation and migration of HCC cells and induces aberrant histone acetylation in HCC. These findings highlight a potential therapeutic approach in targeting the HDAC4/Sp1/miR-200a regulatory network for the treatment of HCC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/hep.24606 | DOI Listing |
Alzheimers Dement
December 2024
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Background: Aging is a time-dependent deterioration of physiological functions that occurs in both humans and animals. Within the brain, aging cells gradually become dysfunctional through a complex interplay of intrinsic and extrinsic factors, ultimately leading to behavioral deficits and enhanced risk of neurodegenerative diseases such as Alzheimer's disease (AD). The characteristics of normal aging are distinct from those associated with age-related diseases and it is important to understand the processes that contribute to this pathological divergence.
View Article and Find Full Text PDFBackground: In Alzheimer's disease (AD), histone acetylation is disrupted, suggesting loss of transcriptional control. Moreover, converging evidence suggests an age- and AD-dependent loss of transcription controlled by all-trans-retinoic acid (ATRA), the bioactive metabolite of vitamin A (VA). Antioxidant depletion causes oxidative stress (OS).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
UMR7364 CNRS UNISTRA, Strasbourg, Alsace, France.
Background: Aging is the main risk factor of cognitive neurodegenerative diseases such as Alzheimer's disease, with epigenome alterations as a contributing factor, however, it is not clear which biological mechanisms are common or disease-specific. Here we investigated epigenomic/genomic signatures in the hippocampus of mouse models of aging and of tauopathy, an AD-related feature.
Methods: Aging was modelled by comparing 18-month- versus 3-month-old WT mice.
Alzheimers Dement
December 2024
University of Pennsylvania, Philadelphia, PA, USA.
Background: Alzheimer's disease (AD) is neurodegenerative disease brought on by a combination of changes in multiple pathways that conglomerate to promote disease progression. AD often occurs alongside comorbid diseases, most often immune or vascular in nature, which have been shown to further increase AD risk. We previously showed that known AD variants also associate with secondary diseases in these categories, including rheumatoid arthritis, ischemic myocardial infarction, and both Type 1 and Type 2 diabetes.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland, OH, USA.
Background: The emerging tools of protein-protein interactome network offer a platform to explore not only the molecular complexity of human diseases, but also to identify risk genes and drug targets. Integration of the genome, transcriptome, proteome, and the interactome networks are essential for such identification, including Alzheimer's disease (AD), Parkinson disease (PD), and Amyotrophic lateral sclerosis (ALS) METHOD: In this study, we performed multi-modal analyses of cross-species protein interactome networks and human brain functional genomics data to identify risk genes and drug targets for neurodegenerative diseases. We presented a multi-view topology-based deep learning framework to identify disease-associated genes for cross-species interactome (TAG-X).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!